Advertisement
Journal of Investigative Dermatology Home

Statin Use and Skin Cancer Risk: A Prospective Cohort Study

  • Marie Al Rahmoun
    Affiliations
    Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Gustave Roussy, "Exposome and Heredity" Team, CESP, F-94805, Villejuif, France
    Search for articles by this author
  • Reza Ghiasvand
    Affiliations
    Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway

    Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
    Search for articles by this author
  • Manon Cairat
    Affiliations
    Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France
    Search for articles by this author
  • Yahya Mahamat-Saleh
    Affiliations
    Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Gustave Roussy, "Exposome and Heredity" Team, CESP, F-94805, Villejuif, France
    Search for articles by this author
  • Iris Cervenka
    Affiliations
    Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Gustave Roussy, "Exposome and Heredity" Team, CESP, F-94805, Villejuif, France
    Search for articles by this author
  • Gianluca Severi
    Affiliations
    Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Gustave Roussy, "Exposome and Heredity" Team, CESP, F-94805, Villejuif, France

    Department of Statistics, Computer Science and Applications “G. Parenti”, University of Florence, Italy
    Search for articles by this author
  • Marie-Christine Boutron-Ruault
    Affiliations
    Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Gustave Roussy, "Exposome and Heredity" Team, CESP, F-94805, Villejuif, France
    Search for articles by this author
  • Trude Eid Robsahm
    Affiliations
    Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
    Search for articles by this author
  • Author Footnotes
    6 These authors contributed equally to this work.
    Marina Kvaskoff
    Footnotes
    6 These authors contributed equally to this work.
    Affiliations
    Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Gustave Roussy, "Exposome and Heredity" Team, CESP, F-94805, Villejuif, France
    Search for articles by this author
  • Author Footnotes
    6 These authors contributed equally to this work.
    Agnès Fournier
    Correspondence
    Correspondence: Agnès Fournier, Inserm U1018, “Exposome, Heredity, Cancer, and Health” Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif Cedex, France.
    Footnotes
    6 These authors contributed equally to this work.
    Affiliations
    Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, Gustave Roussy, "Exposome and Heredity" Team, CESP, F-94805, Villejuif, France
    Search for articles by this author
  • Author Footnotes
    6 These authors contributed equally to this work.
Published:October 22, 2021DOI:https://doi.org/10.1016/j.jid.2021.10.010
      Epidemiological studies on statin use in relation to skin cancer risk are scarce and yielded conflicting results. We explored this association in Etude Epidémiologique auprès de femmes de l’Education Nationale, a prospective cohort of French women born in 1925–1950. Health and lifestyle data were self-reported biennially and matched with drug reimbursement data, allowing the identification of participants’ statin use since 2004. Multivariable cause-specific hazards regression models adjusted for skin cancer risk factors estimated hazard ratios with 95% confidence intervals. Over 2004–2014, 455 cutaneous melanoma, 1,741 basal cell carcinoma, and 268 squamous cell carcinoma cases were ascertained among 62,473 women. Compared with never use, there were no associations between ever use of statins and melanoma (hazard ratio = 1.16, 95% confidence interval = 0.94–1.44) or squamous cell carcinoma (hazard ratio = 0.89, 95% confidence interval = 0.66–1.19) risks and a decrease in basal cell carcinoma risk with ever use of statins (hazard ratio = 0.89, 95% confidence interval = 0.79–0.996). We found no trend of increasing or decreasing risks with dose, duration of use, time since first use, or age at first use and no statistically significant effect modification by pigmentary traits or residential UVR exposure. Because of the limited number of studies evaluating the associations between the use of statins and the risks of melanoma, basal cell carcinoma, and squamous cell carcinoma, these findings would deserve further investigation in other settings.

      Abbreviations:

      BCC (basal cell carcinoma), BMI (body mass index), CI (confidence interval), DDD (defined daily dose), E3N (Etude Epidémiologique auprès de femmes de l’Education Nationale), HR (hazard ratio), KC (keratinocyte), SCC (squamous cell carcinoma)
      To read this article in full you will need to make a payment
      Purchase one-time access
      Society Members (SID/ESDR), remember to log in for access.
      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alrashidi A.
        • Rhodes L.E.
        • Sharif J.C.H.
        • Kreeshan F.C.
        • Farrar M.D.
        • Ahad T.
        Systemic drug photosensitivity—culprits, impact and investigation in 122 patients.
        Photodermatol Photoimmunol Photomed. 2020; 36: 441-451
        • Clavel-Chapelon F.
        • E3N Study Group
        Cohort profile: the French E3N cohort study.
        Int J Epidemiol. 2015; 44: 801-809
        • Davies J.T.
        • Delfino S.F.
        • Feinberg C.E.
        • Johnson M.F.
        • Nappi V.L.
        • Olinger J.T.
        • et al.
        Current and emerging uses of statins in clinical therapeutics: a review.
        Lipid Insights. 2016; 9: 13-29
        • Didona D.
        • Paolino G.
        • Bottoni U.
        • Cantisani C.
        Non melanoma skin cancer pathogenesis overview.
        Biomedicines. 2018; 6: 6
        • Ferlay J.
        • Colombet M.
        • Soerjomataram I.
        • Mathers C.
        • Parkin D.M.
        • Piñeros M.
        • et al.
        Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
        Int J Cancer. 2019; 144: 1941-1953
        • Gandini S.
        • Sera F.
        • Cattaruzza M.S.
        • Pasquini P.
        • Picconi O.
        • Boyle P.
        • et al.
        Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure.
        Eur J Cancer. 2005; 41: 45-60
        • Gandini S.
        • Sera F.
        • Cattaruzza M.S.
        • Pasquini P.
        • Zanetti R.
        • Masini C.
        • et al.
        Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors.
        Eur J Cancer. 2005; 41: 2040-2059
        • Garcia-Acosta S.
        • Clavel-Chapelon F.
        Gestion des données manquantes, aberrantes et incohérentes dans l'étude de cohorte E3N [Dealing with missing, abnormal and incoherent data in E3N cohort study].
        Rev Epidemiol Sante Publique. 1999; 47 ([in French]): 515-523
        • Gaulin C.
        • Sebaratnam D.F.
        • Fernández-Peñas P.
        Quality of life in non-melanoma skin cancer.
        Australas J Dermatol. 2015; 56: 70-76
        • Gniadecki R.
        Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis.
        Biochem Biophys Res Commun. 2004; 320: 165-169
        • Goldstein M.R.
        • Mascitelli L.
        • Pezzetta F.
        The double-edged sword of statin immunomodulation.
        Int J Cardiol. 2009; 135: 128-130
        • Haukka J.
        • Sankila R.
        • Klaukka T.
        • Lonnqvist J.
        • Niskanen L.
        • Tanskanen A.
        • et al.
        Incidence of cancer and statin usage--record linkage study.
        Int J Cancer. 2010; 126: 279-284
        • Jacobs E.J.
        • Newton C.C.
        • Thun M.J.
        • Gapstur S.M.
        Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort.
        Cancer Res. 2011; 71: 1763-1771
        • Kubatka P.
        • Kruzliak P.
        • Rotrekl V.
        • Jelinkova S.
        • Mladosievicova B.
        Statins in oncological research: from experimental studies to clinical practice.
        Crit Rev Oncol Hematol. 2014; 92: 296-311
        • Li X.
        • Wu X.B.
        • Chen Q.
        Statin use is not associated with reduced risk of skin cancer: a meta-analysis.
        Br J Cancer. 2014; 110: 802-807
        • Lin B.M.
        • Li W.Q.
        • Cho E.
        • Curhan G.C.
        • Qureshi A.A.
        Statin use and risk of skin cancer.
        J Am Acad Dermatol. 2018; 78: 682-693
        • Ljunggren B.
        • Bjellerup M.
        • Carter D.M.
        Dose-response relations in phototoxicity due to 8-methoxypsoralen and UV-A in man.
        J Invest Dermatol. 1981; 76: 73-75
        • Marguery M.C.
        • Chouini-Lalanne N.
        • Drugeon C.
        • Gadroy A.
        • Bayle P.
        • Journe F.
        • et al.
        UV-B phototoxic effects induced by atorvastatin.
        Arch Dermatol. 2006; 142: 1082-1084
        • Miller D.D.
        • Cowen E.W.
        • Nguyen J.C.
        • McCalmont T.H.
        • Fox L.P.
        Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity.
        Arch Dermatol. 2010; 146: 300-304
        • Monteiro A.F.
        • Rato M.
        • Martins C.
        Drug-induced photosensitivity: photoallergic and phototoxic reactions.
        Clin Dermatol. 2016; 34: 571-581
        • Nardi G.
        • Lhiaubet-Vallet V.
        • Leandro-Garcia P.
        • Miranda M.A.
        Potential phototoxicity of rosuvastatin mediated by its dihydrophenanthrene-like photoproduct.
        Chem Res Toxicol. 2011; 24: 1779-1785
        • O’Gorman S.M.
        • Murphy G.M.
        Photosensitizing medications and photocarcinogenesis.
        Photodermatol Photoimmunol Photomed. 2014; 30: 8-14
        • Pintilie M.
        Analysing and interpreting competing risk data.
        Stat Med. 2007; 26: 1360-1367
        • Pottegård A.
        • Hallas J.
        New use of prescription drugs prior to a cancer diagnosis.
        Pharmacoepidemiol Drug Saf. 2017; 26: 223-227
        • Ray W.A.
        Evaluating medication effects outside of clinical trials: new-user designs.
        Am J Epidemiol. 2003; 158: 915-920
        • Siiskonen S.J.
        • Koomen E.R.
        • Visser L.E.
        • Herings R.M.
        • Guchelaar H.J.
        • Stricker B.H.
        • et al.
        Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma.
        Eur J Clin Pharmacol. 2013; 69: 1437-1444
        • Tang J.Y.
        • So P.L.
        • Epstein Jr., E.H.
        Novel Hedgehog pathway targets against basal cell carcinoma.
        Toxicol Appl Pharmacol. 2007; 224: 257-264
        • Verdebout J.
        A European satellite-derived UV climatology available for impact studies.
        Radiat Prot Dosimetry. 2004; 111: 407-411
        • Wang A.
        • Stefanick M.L.
        • Kapphahn K.
        • Hedlin H.
        • Desai M.
        • Manson J.A.
        • et al.
        Relation of statin use with non-melanoma skin cancer: prospective results from the Women’s Health Initiative.
        Br J Cancer. 2016; 114: 314-320
        • Weintraub W.S.
        Perspective on trends in statin use.
        JAMA Cardiol. 2017; 2: 11-12
        • World Health Organization
        WHOCC - ATC/DDD Index.
        https://www.whocc.no/atc_ddd_index/
        Date: 2019
        Date accessed: November 26, 2020
        • World Health Organization
        Ultraviolet (UV) radiation and skin cancer.
        • Yang K.
        • Marley A.
        • Tang H.
        • Song Y.
        • Tang J.Y.
        • Han J.
        Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies.
        Oncotarget. 2017; 8: 75411-75417